Outcomes of neoadjuvant chemotherapy in BRCA1/2 mutation positive women with advanced stage Müllerian cancer

      Recent evidence shows that ovarian cancer patients with germline BRCA1/2 mutations have improved survival. This is felt to be related, at least in part, to an enhanced response to DNA damage mediated by platinum-based chemotherapy. It is unknown whether this enhanced response exists for neoaduvant chemotherapy. The objective of this study was to investigate the surgical and clinical outcomes in patients with germline BRCA1/2 mutation who received neoadjuvant chemotherapy (NACT) for advanced stage Mullerian cancer.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Gynecologic Oncology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect